Study of Pembrolizumab and Radiotherapy in Liver Cancer
Status:
Recruiting
Trial end date:
2022-04-02
Target enrollment:
Participant gender:
Summary
This is a phase 2 study whose purpose is to assess the efficacy of the combination of
pembrolizumab and stereotactic body radiotherapy (SBRT) in patients with advanced
hepatocellular carcinoma (HCC) who have experienced disease progression after treatment with
sorafenib.